STAT6

STAT6 Full Name

signal transducer and activator of transcription 6, interleukin-4 induced

STAT6 Introduction

Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family of intracellular transcription factors that plays a central role in mediating cytokine-induced signal transduction from the cell membrane to the nucleus, where it activates specific gene expression programs. STAT6 is encoded by the STAT6 gene located on human chromosome 12q13.3 and is primarily activated by the type 2 cytokines interleukin-4 (IL-4) and interleukin-13 (IL-13) through receptors sharing the IL-4Rα subunit. Upon cytokine binding, receptor-associated Janus kinases (JAKs) phosphorylate STAT6 on a critical tyrosine residue, leading to its dimerization and translocation to the nucleus where it binds to DNA and regulates transcription of target genes, including those involved in immune regulation and surface markers such as MHC class II molecules and CD23. This IL-4/IL-13-STAT6 axis underpins its essential role in Th2 cell differentiation and immunoglobulin class switching, particularly for IgE and IgG1 production in B cells, which are hallmarks of adaptive immunity's type 2 responses.

Figure 1.The STAT6 signaling pathway. (Sources: STAT6 Gain-of-Function International Consortium; 2024)

Functionally, STAT6 is indispensable for orchestrating type 2 immune responses and has been extensively studied using gene-targeted mouse models, which revealed that STAT6 deficiency profoundly disrupts IL-4-mediated activities such as B-cell proliferation, upregulation of surface antigens, and Th2 cell development. In the absence of STAT6, IL-4 cannot effectively induce these key immunologic outcomes, demonstrating the transcription factor's non-redundant role in these pathways. Beyond classical Th2 differentiation, STAT6 influences gene expression in multiple cell types, contributing to phenomena like alternative macrophage activation (M2 polarization) and context-dependent regulation of cell growth and apoptosis. Some research also suggests roles for STAT6 in non-immune tissues, where it may affect cellular differentiation processes such as myogenesis, though these functions can be complex and independent of IL-4 signaling.

Clinically, dysregulation of STAT6 signaling is implicated in allergic and inflammatory diseases such as asthma, atopic dermatitis, eosinophilic disorders, and food allergies, where excessive Th2-type responses and IgE production drive pathology. STAT6-deficient animals resist key features of allergic airway disease, including airway hyperresponsiveness and mucus hypersecretion, highlighting its potential as a therapeutic target in allergic conditions. Beyond allergy, aberrant STAT6 activity has been linked to cancer progression, particularly within the tumor microenvironment; for example, in lung carcinoma and other tumors where IL-4/STAT6 signaling can promote alternative macrophage activation and support tumor growth or metastasis. Because of its pivotal role in immune regulation and disease, STAT6 is a focus for both biomarker development and targeted interventions, and products such as antibodies, assays, and gene editing tools that target STAT6 or its pathway components are widely used in research to probe its biology and therapeutic potential.

Alternate Names for STAT6

STAT6; signal transducer and activator of transcription 6, interleukin-4 induced; STAT6B; STAT6C; D12S1644; IL-4-STAT; signal transducer and activator of transcription 6; STAT, interleukin4-induced; transcription factor IL-4 STAT;

• 1. STAT6 Gain-of-Function International Consortium; STAT6 Gain-of-Function International Consortium. Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond. Trends Immunol. 2024, 45(2):138-153.